Search Results

You are looking at 1 - 1 of 1 items for

  • Author or Editor: Deepali Kumar x
  • Refine by Content Type: All x
Clear All Modify Search
Victoria Hall and Deepali Kumar

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had a significant impact on transplantation, with mortality rates in transplant recipients ranging from 10% to 20% (1). Although some antiviral and anti-inflammatory therapies for COVID-19 have become available, they need to be given within a short time window during the course of illness to be effective (2, 3). Thus, the recent US Food and Drug Administration (FDA) Emergency Use Authorization of highly efficacious mRNA-based SARS-CoV-2 vaccines by Pfizer/BioNTech and Moderna provides hope for reducing infection rates (4).

Both